Green tea is now recognized as the most effective cancer preventive beverage. In one study, 10 Japanese-size cups of green tea daily supplemented with tablets of green tea extract limited the recurrence of colorectal polyps in humans to 50%. Thus, cancer patients who consume green tea and take anticancer drugs will have double prevention. We studied the effects of combining (−)-epigallocatechin gallate (EGCG) and anticancer drugs, focusing on inhibition of cell growth and induction of apoptosis. Numerous anticancer drugs, such as tamoxifen, COX-2 inhibitors, and retinoids were used for the experiments, and the combination of EGCG and COX-2 inhibitors consistently induced the enhancement of apoptosis. To study the mechanism of the enhancement, we paid special attention to the enhanced expressions of DDIT3 (growth arrest and DNA damage-inducible 153, GADD153), GADD45A, and CDKN1A (p21/WAF1/CIP1) genes, based on our previous evidence that a combination of EGCG and sulindac specifically induced upregulated expression of GADD153 and p21 genes in PC-9 lung cancer cells. The synergistic enhancements of apoptosis and GADD153 gene expression in human non-small cell lung cancer cells by the combination of EGCG and celecoxib were mediated through the activation of the MAPK signaling pathway. This article reviews the synergistic enhancement of apoptosis, gene expression, and anticancer effects using various combinations of EGCG and anticancer drugs, including the combination of (−)-epicatechin (EC) and curcumin. Based on the evidence, we present a new concept: green tea catechins as synergists with anticancer drugs. (Cancer Sci 2011; 102: 317–323)
“Cancer chemoprevention” was defined in 1976,(1) and Michael Sporn(2) introduced the term “combination cancer chemoprevention” in the journal Nature in 1980. He defined the term as the combined use of several drugs with different mechanisms of action exerting marked synergistic preventive effects. In 1983, we began to study the cancer preventive activity of green tea catechins.(3,4) Green tea extract chemically contains at least four tea catechins: EGCG, ECG, EGC, and EC. The first three catechins induce cancer preventive activities, whereas EC is inactive.(5) We first reported that combinations with the active catechins and inactive EC induced synergistic effects on induction of apoptosis and inhibition of cell growth of human lung cancer cell line PC-9, and inhibition of TNF-α release from BALB/3T3 cells treated with okadaic acid, a tumor promoter.(6) This suggests that whole green tea, which is a mixture of green tea catechins, is a more effective and practical cancer preventive than green tea catechins alone.(6) Using tritium (3H)-EGCG we showed that EC induced the enhanced incorporation of 3H-EGCG and other active green tea catechins into cells.(6) In addition, we recently showed that drinking 10 cups of green tea supplemented with green tea tablets significantly (50%) prevented recurrence of colorectal adenomas in patients who had received polypectomy 1 year before, and it also reduced the size of adenomas.(7) These exciting results prompted us to think that green tea catechins together with anticancer agents are effective cancer treatments. Our study on cancer prevention with green tea thus moves to focus on a new strategy of cancer treatment based on a combination of green tea catechins and anticancer drugs.
We studied the effects of anticancer drugs tamoxifen, sulindac, celecoxib, and retinoids in combination with EGCG or green tea extract. Although all anticancer drugs are structurally and functionally different, the combination with EGCG and an anticancer drug synergistically enhanced the induction of apoptosis 10–15 times as strongly as any anticancer drug alone in PC-9 cells.(6,8) Moreover, cotreatment with green tea extract and sulindac showed enhanced prevention of intestinal tumor development in Min mice.(9) Using a human cancer cDNA expression array, we found that a combination of EGCG and sulindac induced upregulated expression of DDIT3 (GADD153) and CDKN1A (p21/WAF1/CIP1) genes, and downregulated expression of four genes, PLAT (T plasminogen activator), tissue inhibitors of metalloproteinase (TIMP3), IL1B (IL-1β), and ITGB4 (integrin β4).(3,10) These significant results led us to write a review article on a new strategy of cancer treatment based on the combination of EGCG and anticancer drugs.
Curcumin is a phenolic compound present in the plant Curcuma longa (L.) making up 2–5% of total spices in turmeric, a popular spice in India and neighboring countries.(11,12) We recently reported that the combination of EC, an inactive catechin, and curcumin induced cancer preventive effects associated with enhanced induction of GADD153 and GADD45 gene expression.(13) The results gave us a hypothesis indicating that numerous anticancer compounds that are present in vegetables and foods can induce cancer preventive activity in combination with green tea catechins. Weinstein and colleagues and our research group both reported enhanced anticancer effects by a combination of EGCG and anticancer drugs such as 5-FU, taxol, and gefitinib.(14–16) The combination of green tea catechins and anticancer drugs induces synergistic enhancement of expression of the GADD153 gene, resulting in a new mechanism of anticancer treatment that is different from that of green tea catechin or anticancer drugs alone. We anticipate that the combination cancer treatment with green tea catechins and anticancer drugs will be an effective method to enhance therapeutic effects, and that this strategy will reduce the adverse effects of anticancer drugs in cancer patients.
Combination of EGCG and tamoxifen
Tamoxifen is an anti-estrogenic compound used for prevention of breast cancer.(17) The combination of EGCG (75 and 100 μM) and tamoxifen (5–200 μM) induced apoptosis in PC-9 cells more strongly than EGCG alone or tamoxifen alone. Table 1 shows that apoptosis was induced in 27.3% of cells by cotreatment with 100 μM EGCG and 10 μM tamoxifen, a 1.3-fold additive enhancement.(6) The combination of EGCG and tamoxifen also induced the inhibition of TNF-α release from BALB/3T3 cells treated with okadaic acid, a tumor promoter,(6) along with the inhibition of cell growth in human breast cancer cell line MCF-7 (twofold enhancement, data not shown).(6) Specifically, we showed that TNF-α is an endogenous tumor promoter and cancer mediator, using TNF-α deficient mice.(18–20) Thus, our results significantly showed that the essential mechanism of tumor promotion was inhibited by the combination. Another research group found enhanced antitumor effects on the development of spontaneous mammary tumors in C3H/Ouj mice with a combination of green tea extract and tamoxifen.(21) This combination also inhibited proliferation of ER-positive (MCF-7, ZR-75–1, and T-47D) and ER-negative (MDA-MB-231) human breast cancer cells, and inhibited growth of xenografts of MCF-7 and MDA-MB-231 in nude mice more strongly than tamoxifen alone.(22,23) The combination of EGCG or green tea extract with tamoxifen increases preventive effects on breast cancer cells regardless of their ER status, thus it may be an ideal tool for prevention of breast cancer in general.
Table 1. Synergistic induction of apoptosis and GADD153 gene expression by combining (−)-epigallocatechin gallate (EGCG) and anticancer drugs in PC-9 lung cancer cells
Induction of apoptosis† % of apoptotic cells (fold)‡
Expression of GADD153 gene fold expression (fold)§
†Percent of apoptotic cells was determined by flow cytometry. ‡Fold enhancement by combination with EGCG was calculated compared with that of anticancer drug alone. Percentages of apoptotic cells in non-treated and EGCG-treated cells were 5.0 and 6.1%, respectively. §Expression of GADD153 gene is the fold-expression compared with that of non-treated PC-9 cells as assessed by RT-PCR. ¶Cells were treated with combinations of 100 μM EGCG and 10 μM tamoxifen, 50 μM sulindac, 10 μM celecoxib, 10 μM all-trans-retinoic acid (ATRA), 10 μM 13-cis-retinoic acid (RA), 10 μM 9-cis-RA, and 50 μM N-(4-hydroxyphenyl)retinamide (4-HPR) for 24 h (for gene expression) or 40 h (for apoptosis). n.d., not determined.
Combination of EGCG and COX-2 inhibitors
EGCG and sulindac. Sulindac, a non-selective COX-2 inhibitor and non-steroidal anti-inflammatory drug, suppresses colorectal tumorigenesis in patients with familial adenomatous polyposis, whose condition is caused by germline mutation of the adenomatous polyposis coli (APC) gene.(24) Although sulindac is a preventive drug for colon cancer in patients with familial adenomatous polyposis, its chronic treatment is restricted because it also causes bleeding and peptic ulceration in the gastrointestinal tract. The combination with catechins may overcome this side-effect by decreasing the concentration of sulindac.
A combination of 100 μM EGCG and 50 μM sulindac increased the induction of apoptosis 10.5-fold in PC-9 cells (Table 1), whereas sulindac alone at concentrations up to 100 μM did not induce any apoptosis.(6) We next looked at the synergistic effects of the combination with EGCG and metabolites of sulindac – sulindac sulfide and sulindac sulfone – on induction of apoptosis in PC-9 cells. The combination of 75 μM EGCG and 10 μM sulindac induced apoptosis more than 20 times stronger than sulindac alone. Combinations of 75 μM EGCG and the same concentrations of sulindac sulfide, an inhibitor of COX-1 and COX-2, and with EGCG and sulindac sulfone, an inactive metabolite, also synergistically induced apoptosis of the cells (data not shown).(25) We therefore believe that the synergistic effects on apoptosis by the combination are not necessarily related to inhibition of COX.(25)
Moreover, the combination synergistically inhibited cell growth of mouse colon adenocarcinoma cell line, Colon 26, more strongly than EGCG alone or sulindac alone (data not shown). To study the enhanced effects of the combination of EGCG and sulindac, Min mice, which have a germline mutation of the murine Apc gene, were given drinking water with 0.1% green tea extract and diet containing 0.03% sulindac for 10 weeks. Table 2 shows the additive inhibition of tumor formation by the combination: control Min mice without any treatment developed 72.3 ± 28.3 tumors per mouse at 16 weeks of age, and the combination with green tea extract and sulindac reduced the number of tumors to 32.0 ± 18.7 tumors per mouse, a decrease of 44.3%.(9) The combination also resulted in significantly smaller tumor size than in any of the other groups.(9) In addition, Ohishi et al.(26) reported that a combination of 0.01% EGCG in drinking water and sulindac (10 mg/kg, 3 per week) synergistically suppressed the formation of aberrant crypt foci from 46.2 ± 4.9 to 10.0 ± 3.2 in F344 rats induced with azoxymethane.
Table 2. Synergistic inhibition of tumor formation by combining green tea extract and COX-2 inhibitors
Tumor incidence (%)
Average no. tumors/mouse (%)
†Multiple intestinal neoplasia (Min) mice were treated with 0.1% green tea extract in drinking water and 0.03% sulindac in diet. ‡A/J mice were injected i.p. with 100 mg/kg 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), then treated with 0.3% green tea extract in drinking water and 0.05% celecoxib in diet. §P < 0.05.
Modulation of gene expression by combination of EGCG and sulindac. The cDNA expression array made it possible for us to monitor the expression levels of a multitude of genes simultaneously.(27) Using Clontech’s Atlas cDNA expression array, which deals with 588 known cancer-related genes, we found that treatment with EGCG in PC-9 cells induced upregulation of one gene, retinoic acid receptor α1, and downregulation of four genes, MAP3KI4 (NF-κB inducing kinase), DAPK1 (death-associated protein kinase I), rho B, and tyrosine–protein kinase (SKY).(10,28) The downregulation of NIK gene expression resulted in less activation of the NF-κB pathway, because NIK is an activator of IKKα, and related to constitutive activation of the NF-κB pathway, one of the essential signals for cancer development.
Using the same experimental procedure as with the human cancer cDNA expression array, the levels of gene expression in PC-9 cells treated with 200 μM EGCG and 10 μM sulindac, with 200 μM EGCG alone, or with 10 μM sulindac alone, using non-treated cells as a control, were determined. The combination induced upregulated expression of GADD153 and p21 genes dramatically, approximately 10.2-fold and threefold, respectively, whereas those genes were not affected by treatments with either EGCG or sulindac alone.(3,10) The upregulation of the GADD153 gene induces apoptosis in the cells,(29) and upregulation of the p21 gene is related to inhibition of cell proliferation by blocking the cell cycle.(30) Furthermore, the combination induced downregulated expression of T plasminogen activator, TIMP3, IL-1β, and integrin β4 genes, all <0.3-fold.(3,10) These altered genes were completely different from the previously mentioned genes found in EGCG treated cells, and this finding is our first evidence that the combination with EGCG and sulindac induces some new mechanism of cancer treatment associated with expression patterns in genes, patterns not observed with EGCG alone or sulindac alone.(3,10) These results were well supported by evidence that the combination induces synergistic effects on apoptosis of the cells (Table 1). Upregulation of the GADD153 gene was much stronger than that of the p21 gene, as mentioned above, and we think that the enhanced expression of the GADD153 gene is a new mechanism of combination cancer prevention.
EGCG and celecoxib. Celecoxib is a COX-2 selective inhibitor, and both sulindac and EGCG are non-selective COX-2 inhibitors. Celecoxib is a promising preventive drug but its long-term use causes adverse cardiovascular effects.(31) A combination of EGCG and celecoxib was used on three human non-small cell lung cancer cell lines, PC-9, A549, and ChaGo K-1, to determine the induction of apoptosis and upregulation of GADD153 gene expression. The combination of 100 μM EGCG and 10 μM celecoxib induced the apoptosis of PC-9 cells approximately 16.1-fold, along with synergistic expression of the GADD153 gene (12.9-fold) (Table 1). As a result of the strong gene expression, a large amount of GADD153 protein was confirmed in the cells treated with the combination. Synergistic induction of apoptosis by the combination was also observed in both A549 and ChaGo K-1 cells, along with enhanced GADD153 gene expression.(8) However, the expression of other apoptosis related genes, such as p21 and GADD45, was not enhanced by the combination.
The synergistic inhibition of tumor formation by the combination of green tea extract and celecoxib was also confirmed in NNK-induced lung tumorigenesis in A/J mice. Female A/J mice were given an i.p. injection of 100 mg/kg body weight of NNK, and 3 days later mice began treatment with 0.3% green tea extract in drinking water and 0.05% celecoxib in diet, continuing for 16 weeks. The combination significantly reduced tumor incidence (from 100% to 73.3%) and the average number of tumors/mouse (from 3.2 to 1.1), a 34.4% inhibition (Table 2).(32) The results clearly indicated effective cancer prevention in the lungs by a combination of EGCG and celecoxib.
Synergistic anticancer effects in vitro and in vivo on human prostate cancer cells were also achieved by the combination of EGCG and COX-2 selective inhibitors. Specifically, new COX-2 selective inhibitor NS398, in combination with EGCG, enhanced induction of apoptosis and inhibited growth of LNCaP, PC-3, and CWR22Rν1 cells, and the combination of green tea catechin and celecoxib resulted in enhanced inhibition of tumor growth in athymic nude mice implanted with CWR22Rν1 cells.(33)
Enhancement of GADD153 gene expression and MAPK signaling pathway
GADD153, also known as CHOP (C/EBP homology protein), is a transcription factor belonging to the CCAAT/enhancer binding protein (C/EBP) family.(34)GADD153 gene expression becomes highly upregulated in cells as a result of various stress conditions, and some reports show that GADD153 is directly involved in the regulation of apoptosis, mediated through activation of the MAPK signaling pathway.(35) The combination of 100 μM EGCG and celecoxib at various concentrations (1, 10, and 50 μM) dose-dependently induced phosphorylation of ERK1/2 and p38 MAPK in PC-9 cells 1 h after treatment, indicating the significant activation of ERK1/2 and p38 (Fig. 1A).
Using specific inhibitors of the protein kinases PD98059 (a specific ERK1/2 inhibitor), UO126 (a selective MEK inhibitor), SB203580 (a specific p38 MAPK inhibitor), and calphostin C (a specific protein kinase C inhibitor), we studied the involvement of ERK1/2 activity in both expression of the GADD153 gene and synergistic induction of apoptosis by the combination. Pretreatments with PD98059 and UO126 dose-dependently reduced the expression of GADD153 gene upregulated by the combination, but other inhibitors, SB203580 and calphostin C, were not effective (Fig. 1B). Moreover, two inhibitors, PD98059 and UO126, dose-dependently inhibited the synergistic induction of apoptosis by the combination (data not shown).(8) Similar results were also obtained in other lung cancer cell lines, A549 and ChaGo K-1. All the results indicate that the combination of EGCG and celecoxib induced the activation of the ERK signaling pathway, followed by enhanced expression of the GADD153 gene, and then induction of apoptosis.
Combination of EGCG and retinoids
To extend our concept of the combination cancer treatment, we studied the effects of combining EGCG and retinoids. Numerous retinoids have been developed, and their mechanisms of action are varied.(36) Four retinoids, ATRA, 13-cis-RA, 9-cis-RA, and 4-HPR, were used for our experiments. The combination of 100 μM EGCG with 10 μM ATRA, or 10 μM 13-cis-RA, or 10 μM 9-cis-RA, induced dramatically upregulated expression of the GADD153 gene in PC-9 cells 24 h after treatment (Table 1). However, 4-HPR alone induced the enhancement, and did not show any further enhancement with EGCG (Table 1). Thus we think that 4-HPR acts differently from other retinoids, mediated through retinoic acid receptor-independent mechanisms. The synergistically enhanced expression of the GADD153 gene by the combination of EGCG with the retinoids ATRA, 13-cis-RA, and 9-cis-RA showed patterns similar to those of apoptosis induction (Table 1).(37) Although the mechanisms of these three retinoids are different from those of the two COX-2 inhibitors, the combination of retinoids with EGCG induced similar, strong inductions of GADD153 gene expression and synergistic induction of apoptosis in human cancer cells.
Combination of EC and curcumin
Curcumin is traditionally well known to have therapeutic effects on various types of diseases.(13) The combination of EGCG and curcumin showed synergistic interactions in growth inhibition and increased sigmoidicity of the dose-effect curves in human oral epithelial cells,(38) and the combination also provided higher efficacy in inhibiting ERα breast cancer cell growth in vitro and in vivo.(39) Although the cancer preventive activity of curcumin has been intensively studied in animal experiments, human studies on cancer prevention with curcumin have not yet been reported, due to the low bioavailability, which means the poor absorption of curcumin into the cells and tissues, in contrast to catechins.
To overcome this low bioavailability, we used a combination of curcumin with catechin in experiments, by examining growth inhibition of PC-9 cells and induction of apoptosis. As EGCG and EC showed very similar synergistic effects with curcumin on these tests, we chose EC for further experiments, because EC is a relatively inexpensive compound compared with EGCG. The combination of 200 μM EC and 20 μM curcumin significantly induced much higher inhibition of human lung cancer cell lines PC-9 and A549 than either EC alone or curcumin alone (data not shown). The combination significantly increased induction of apoptosis to 59.0% of PC-9 cells after 72 h, whereas treatment with EC alone showed a marginal effect, and that with curcumin alone induced 42.3% apoptosis of the cells.(13) The results suggest that the enhancement of growth inhibition by the combination of EC and curcumin is also associated, in part, with the induction of apoptosis.
The combining of EC (100 and 200 μM) and 20 μM curcumin induced 1.7- and 2.1-fold enhancement of GADD153 gene expression in PC-9 cells after 24 h, whereas treatment with EC alone or with curcumin alone was marginal.(13) In addition, the synergistic enhancement of GADD45 gene expression was observed by the combination in PC-9 cells. However, the combination induced synergistic expression of the GADD153 gene, but not the GADD45 gene, in A549 cells, and synergistic enhancement of p21 gene expression was observed in PC-9 cells, but not in A549 cells.(13)
To characterize the molecular nature of the induction of apoptosis and the enhanced expressions of GADD153 and GADD45 genes, siRNA duplexes were used to knock down their mRNA levels in PC-9 cells. The treatment of PC-9 cells with siRNAs for GADD153 and GADD45 significantly reduced apoptosis induced by the combination of EC and curcumin as compared with cells with control siRNA, along with the reduction of both mRNA and protein levels of GADD153 and GADD45 genes.(13)
Enhanced incorporation of curcumin with EC
We first found that EC enhanced the incorporation of 3H-EGCG into PC-9 cells by 1.5-fold, and unlabeled EGCG inhibited that of 3H-EGCG dose-dependently (Fig. 2A), suggesting that the presence of EC facilitates 3H-EGCG incorporation into the cells. Therefore, using the spectrophotometric method, we investigated whether EC would enhance the incorporation of intracellular curcumin levels in the cells. As Figure 2(B) shows, the combination of 100 μM EC and 20 μM curcumin significantly increased the amounts of intracellular curcumin approximately 1.3-fold over that with curcumin alone.(13) Thus, EC enhanced the uptake of curcumin into PC-9 cells.
The average daily individual intake of turmeric is approximately 2.0–2.5 g in the Indian subcontinent, or up to 100 mg of curcumin ingestion on a regular basis without any adverse effects.(40) Based on the above-mentioned results, we assume that the combination of 1 g EC and 100 mg curcumin will result in much greater preventive activity than that produced by curcumin alone in humans.
Combinations with EGCG and anticancer drugs
In 2001, I. B. Weinstein’s group reported that EGCG at 0.1 μg/mL markedly enhanced the growth inhibitory effects of 5-FU on human head and neck squamous cell carcinoma lines, YCU-N861 (3.6-fold) and YCU-H891 (45-fold) (Table 3).(14) Interestingly, YCU-H891 cells that are resistant to 5-FU, became sensitive to the drug when combined with EGCG.(14) They also reported that treatment with EGCG inhibited the growth of both YCU-H891 cells and breast cancer cell line BT-474 more strongly than that with taxol alone did.(15) Liang et al. reported that treatment with EGCG significantly reduced the IC50 value for doxorubicin from 36 to 1.9 μg/mL, and that for ECG to 2.3 μg/mL in BEL-7404/DOX cells, and the combination with EGCG and doxorubicin clearly enhanced the reduction of tumor volumes in an in vivo xenograft model inoculated with BEL-7404/DOX cells (Table 3).(41)
Table 3. Enhancements of growth inhibitory effects by combining (−)-epigallocatechin gallate and anticancer drugs
Cancer (cell lines)
Head and neck squamous cell carcinoma (YCU-N861, YCU-H891)
We previously reported that EGCG has a sealing effect as its mechanism of cancer prevention, that is, the treatment of cells with EGCG interrupts the interaction of cellular factors in membrane receptors by covering the cell surface and intracellular organella.(42) In the experiments, we showed that treatment with EGCG inhibited both the activation of EGFR and the EGFR downstream signaling pathway.(42,43) The combination of EGCG and the EGFR tyrosine kinase inhibitor, gefitinib, additively inhibited the growth of human lung cancer cell lines PC-9 and A549, compared with EGCG alone or gefitinib alone.(16) The combination of EGCG and gefitinib more strongly inhibited phosphorylation of EGFR than gefitinib alone.(16) It is important to note that the combination induced expression of the GADD153 gene and apoptosis, whereas gefitinib alone did not induce expression of the GADD153 gene.(16) The synergistic inhibition by the combination of EGCG and another EGFR tyrosine kinase inhibitor, erlotinib, was also observed in five head and neck squamous cell carcinoma cell lines, and the phosphorylations of EGFR and AKT were strongly inhibited, followed by induction of apoptosis (Table 3). Furthermore, antitumor effects of the EGCG and erlotinib combination were shown on xenograft mice bearing Tu212 cells.(44) All the results showed that EGCG probably enhances the sensitivity of cancer cells to various anticancer drugs.
Green tea is recognized as a cancer preventive beverage in Japan, and it is now developing as a cancer preventive drug in the USA and Europe. Two clinical phase II trials carried out in Italy and the USA showed the preventive effects of green tea on prostate cancer in patients with prostate intraepithelial neoplasias and on the high-risk oral premalignant lesion.(45,46)
Considering the significant cancer preventive activity of green tea catechins in humans, we began to study an additional feature of green tea catechins: if patients consume sufficient amounts of green tea and also take anticancer agents, they get double prevention. Several experiments showed that the combination of EGCG and COX-2 inhibitors sulindac and celecoxib, along with retinoids and curcumin, synergistically or additively induced apoptosis and enhanced the expression of GADD153 and GADD45 genes in PC-9 cells. The mechanisms of the enhanced gene expressions were shown to be mediated through activation of the MAPK signaling pathway. It is important to note that these modulations in gene expression are newly induced by the combination, but not by a single compound alone. It may subsequently be found that numerous anticancer compounds that are present in vegetables and foods can induce such synergistic cancer preventive effects with green tea catechins. As green tea catechins increase the anticancer activity of various anticancer drugs, this review presents our new concept of green tea as a synergist with anticancer drugs (Fig. 3).
This work was supported by the Japan Society for the Promotion of Science: Scientific Research on Priority Areas for Cancer Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan; Comprehensive Research on Aging and Health; and Cancer Research from the Ministry of Health, Labor, and Welfare, Japan; Selective Applied and Developed Research, and Green Tea Extracts Research Development for Cancer Prevention by the Department of Agriculture and Forests and the Department of Health and Human Services of Saitama Prefecture, Japan; and the Smoking Research Fund. We thank Dr. Takashi Sugimura, President Emeritus of the National Cancer Center, for his encouragement, and Professor Emeritus Takuo Okuda at the Faculty of Pharmaceutical Sciences of Okayama University for his collaboration. We also thank Mr. Yoshiaki Kitaoka, Mr. Kenta Nakajima, and Mr. Atsushi Takahashi at the Department of Agriculture and Forests of Saitama Prefecture for their fruitful collaborations, and Drs. Kei Nakachi, Kazue Imai, and Sachiko Okabe-Kidokoro, and Mrs. Kaori Suzuki, Miki Kurusu, and Ikuko Shiotani, who worked with us at the Saitama Cancer Center Research Institute. The author (A. S.) is supported by the Japanese Government Monbukagakusho Scholarship Program for doctoral study from the Ministry of Education, Culture, Sports, Science and Technology, Japan and expresses his special thanks to the American Association for Cancer Research and ITO-EN, Ltd for the 2009 AACR-ITO EN, Ltd. Scholar-in-Training Award at the AACR 100th Annual Meeting, Denver, CO, USA.